An analysis of the kinetics of KRAS mutation evolution in these patients further concluded that KRAS mutations had been present before anti-EGFR therapy initiation, in small subclones comprising ∼2000–3000 cancer cells [34]. This evidence concerns the gene KRAS and cancer.